Based on the available information, there is some indication that taking Cosentyx (secukinumab) may impact the effectiveness of live vaccines.
Cosentyx is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that is believed to play a role in inflammation and immune system responses [1].
According to the Centers for Disease Control and Prevention (CDC), live vaccines work by introducing a weakened form of the virus or bacteria that the vaccine is designed to protect against. This weakened form stimulates the immune system to produce a response, which provides protection against future infection [2].
The National Institutes of Health (NIH) published a study that found that monoclonal antibodies, such as Cosentyx, can impact the immune system's response to live vaccines [3]. The study found that the effectiveness of live vaccines may be reduced in people taking monoclonal antibodies, as the drugs can interfere with the immune system's ability to respond to the weakened form of the virus or bacteria in the vaccine.
Therefore, it is important for individuals taking Cosentyx to discuss their vaccination history and any planned vaccinations with their healthcare provider. Healthcare providers may recommend that individuals taking Cosentyx avoid live vaccines or consider alternative vaccination options [2].
In summary, based on the available information, there is a link between Cosentyx and live vaccine potency. Cosentyx can impact the immune system's response to live vaccines, potentially reducing their effectiveness. It is important for individuals taking Cosentyx to discuss their vaccination history and any planned vaccinations with their healthcare provider.
Sources:
[1] DrugPatentWatch. Cosentyx (secukinumab). <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>
[2] Centers for Disease Control and Prevention. Immunocompromised Travelers. <https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-considerations/immunocompromised-travelers>
[3] National Institutes of Health. Impact of monoclonal antibodies on the immune response to live viral vaccines. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386277/>